|
|
Latest Lung Cancer: Small Cell News
Estrogen Alone Does Not Increase Lung Cancer Incidence or Mortality in Postmenopausal Women (8/30/2010)
Among postmenopausal women, hormone therapy with estrogen alone does not appear to increase the risk of getting or dying from lung cancer. These results were published in the Journal of the National Cancer Institute.
Vitamin B6 Associated with Lower Risk of Lung Cancer (6/28/2010)
Individuals with high blood levels of vitamin B6 may be less likely to develop lung cancer compared with their counterparts with lower vitamin B6 levels, according to the results of a study published in the Journal of the American Medical Association.
Some Blood Pressure Drugs May Raise Cancer Risk (6/23/2010)
It appears that angiotensin-receptor blockers (ARBs), a widely used class of blood pressure drugs, may slightly increase the risk of cancer. These findings were published in the Lancet Oncology.
Depression May Persist With Metastatic Cancer (5/27/2010)
A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early online in the Journal of Clinical Oncology.
High Rate of False-positive Results in Lung Cancer Screening with CT Scan (4/28/2010)
Screening for lung cancer using computed tomography (CT) scans can yield a high rate of false-positive results, according to a study published in the Annals of Internal Medicine. False-positive results are risky because they may lead to invasive follow-up testing, financial burden, and anxiety.
Lung Cancer: Small Cell News By Topic
Lung Cancer: Small Cell - Screening/PreventionEstrogen Alone Does Not Increase Lung Cancer Incidence or Mortality in Postmenopausal Women (8/30/2010)
Among postmenopausal women, hormone therapy with estrogen alone does not appear to increase the risk of getting or dying from lung cancer. These results were published in the Journal of the National Cancer Institute.
Vitamin B6 Associated with Lower Risk of Lung Cancer (6/28/2010)
Individuals with high blood levels of vitamin B6 may be less likely to develop lung cancer compared with their counterparts with lower vitamin B6 levels, according to the results of a study published in the Journal of the American Medical Association.
Some Blood Pressure Drugs May Raise Cancer Risk (6/23/2010)
It appears that angiotensin-receptor blockers (ARBs), a widely used class of blood pressure drugs, may slightly increase the risk of cancer. These findings were published in the Lancet Oncology.
High Rate of False-positive Results in Lung Cancer Screening with CT Scan (4/28/2010)
Screening for lung cancer using computed tomography (CT) scans can yield a high rate of false-positive results, according to a study published in the Annals of Internal Medicine. False-positive results are risky because they may lead to invasive follow-up testing, financial burden, and anxiety.
Combined Hormone Replacement Therapy May Increase Women’s Risk of Lung Cancer (4/2/2010)
Women who receive hormone replacement therapy with estrogen plus progestin may have an increased risk of developing lung cancer, according to a study published in the Journal of Clinical Oncology.
Lung Cancer: Small Cell - Limited DiseaseMost Survivors of Lung and Colorectal Cancer Keep Their Jobs (4/14/2010)
Among people diagnosed with nonmetastatic lung or colorectal cancer, the majority return to work, according to a study recently published in Journal of Clinical Oncology. Those who do leave the workforce tend to have worse prognoses and lower socioeconomic status.
Smoking Cessation After Lung Cancer Diagnosis Improves Survival (2/11/2010)
Quitting smoking after a diagnosis of early-stage lung cancer may reduce the risk of cancer recurrence and death. These results were published in the British Medical Journal.
Thalidomide Doesn’t Benefit Patients with Small Cell Lung Cancer (7/22/2009)
Treatment with a combination of thalidomide and chemotherapy did not improve survival among patients with small cell lung cancer, and resulted in a higher risk of blood clots than treatment with chemotherapy alone. The results of this study were published in the Journal of the National Cancer Institute.
Non-Platinum Chemotherapy as Effective for SCLC (10/14/2008)
Chemotherapy regimens that do not contain platinum agents (Platinol and Paraplatin) appear to be just as effective as regimens that do contain platinum agents in the treatment of small cell lung cancer. These results were recently published in the Cochrane Database of Systematic Reviews.
Higher Chemotherapy Dose Intensity Does Not Improve Survival for Small Cell Lung Cancer (4/21/2008)
Increasing the dose intensity of chemotherapy does not appear to improve survival in small cell lung cancer. These results were recently published in the Journal of the National Cancer Institute.
Lung Cancer: Small Cell - Extensive DiseaseDepression May Persist With Metastatic Cancer (5/27/2010)
A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early online in the Journal of Clinical Oncology.
Most Survivors of Lung and Colorectal Cancer Keep Their Jobs (4/14/2010)
Among people diagnosed with nonmetastatic lung or colorectal cancer, the majority return to work, according to a study recently published in Journal of Clinical Oncology. Those who do leave the workforce tend to have worse prognoses and lower socioeconomic status.
Thalidomide Doesn’t Benefit Patients with Small Cell Lung Cancer (7/22/2009)
Treatment with a combination of thalidomide and chemotherapy did not improve survival among patients with small cell lung cancer, and resulted in a higher risk of blood clots than treatment with chemotherapy alone. The results of this study were published in the Journal of the National Cancer Institute.
Gemzar® and Paraplatin® Equivalent to Platinol® and VePesid® for SCLC (12/30/2008)
A combination of Gemzar® (gemcitabine) and Paraplatin® (carboplatin) is as effective as standard Platinol® (cisplatin) and VePesid® (etoposide) for palliative treatment of patients with poor-risk small cell lung cancer (SCLC). The Gemzar/Paraplatin combination is also less toxic, according to the results of a study published in an early online publication of Thorax on September 11, 2008.
Non-Platinum Chemotherapy as Effective for SCLC (10/14/2008)
Chemotherapy regimens that do not contain platinum agents (Platinol and Paraplatin) appear to be just as effective as regimens that do contain platinum agents in the treatment of small cell lung cancer. These results were recently published in the Cochrane Database of Systematic Reviews.
Lung Cancer: Small Cell - RecurrentOral Hycamtin® Approved for Relapsed Small Cell Lung Cancer (10/15/2007)
The United States Food and Drug Administration has approved an oral capsule formulation of the chemotherapy agent Hycamtin® (topotecan) for the treatment of relapsed small cell lung cancer.
Further Results Show Improved Survival with Picoplatin for Small Cell Lung Cancer (9/4/2007)
According to results published in a press release by Poniard Pharmaceuticals, longer follow-up further indicates that the investigative chemotherapy agent picoplatin may improve survival compared to existing therapies in the treatment of patients diagnosed with small cell lung cancer who have previously received platinum-based therapies.
Addition of Gliadel® Wafer to Surgery and Radiation Effective for Brain Metastasis (6/22/2007)
According to an article in Clinical Cancer Research, the addition of Gliadel® Wafer (carmustine polymer wafer) to surgery plus external beam radiotherapy for the treatment of a single brain metastasis is a safe and effective regimen for patients.
Hycamtin® Improves Survival in Patients with Relapsed Small Cell Lung Cancer (12/6/2006)
According to the results of a study published in the Journal of Clinical Oncology, patients with relapsed small cell lung cancer survived longer if they were treated with the oral chemotherapy drug Hycamtin® (topotecan) than if they received no further chemotherapy.
Amrubicin Shows Promise in Relapsed or Refractory Small Cell Lung Cancer (11/30/2006)
According to a study published in the Journal of Clinical Oncology, treatment with the experimental chemotherapy drug amrubicin reduced or eliminated detectable cancer in roughly half of patients with previously-treated small cell lung cancer.
|
|
